6K: Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Ther false
ôøôì áéåè÷ áò"î 2 380
PURPLE BIOTECH LTD
Corporation no: 520031238 12724

Israel Securities Authority   Tel Aviv Stock Exchange   C002 ( Public )   Reported via MAGNA: 10/10/2024
  www.isa.gov.il     www.tase.co.il       Reference: 2024-02-609929 Time of broadcast: 14:42 14:42

Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

ea021729401-6k_purpleEDGAR1_Bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
       

Stock Exchange/Market: NASDAQ CM Date of revision of form structure: 06/08/2024
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com

Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,

Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel